Dr. Langer on the Future of Immunotherapy for Treatment of NSCLC
Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.
Corey J. Langer, MD, director, thoracic oncology, Penn Medicine discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.
Moving forward with immunotherapy, Langer believes that oncologists will have answers to important ongoing questions. Who is more likely to benefit from immunotherapy? Which patients can receive immunotherapy in combination with chemotherapy and which patients should not get immunotherapy? To understand this, Langer suggest personalizing treatment and draw information from the profiles of those patients.
